Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Traws Pharma (TRAW) EBIAT (2016 - 2025)

Traws Pharma (TRAW) has disclosed EBIAT for 14 consecutive years, with -$7.4 million as the latest value for Q4 2025.

  • For Q4 2025, EBIAT rose 75.13% year-over-year to -$7.4 million; the TTM value through Dec 2025 reached $9.2 million, up 105.51%, while the annual FY2025 figure was $9.2 million, 105.51% up from the prior year.
  • EBIAT hit -$7.4 million in Q4 2025 for Traws Pharma, down from -$4.0 million in the prior quarter.
  • Across five years, EBIAT topped out at $21.5 million in Q1 2025 and bottomed at -$123.1 million in Q2 2024.
  • Average EBIAT over 5 years is -$10.6 million, with a median of -$4.5 million recorded in 2021.
  • Year-over-year, EBIAT tumbled 2797.48% in 2024 and then surged 531.27% in 2025.
  • Traws Pharma's EBIAT stood at -$3.8 million in 2021, then crashed by 44.0% to -$5.4 million in 2022, then rose by 22.8% to -$4.2 million in 2023, then plummeted by 615.15% to -$29.9 million in 2024, then surged by 75.13% to -$7.4 million in 2025.
  • According to Business Quant data, EBIAT over the past three periods came in at -$7.4 million, -$4.0 million, and -$915000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.